Washington DC (PRWEB) February 28, 2013
The prescription drug resource site Drugrisks.com is alerting atrial fibrillation patients who take the blood thinner Pradaxa to prevent stroke of new information on the site which shows the maker of the drug has paid for a study which was just released disputing prior warnings over internal bleeding.
“The goal of Drugrisks is to improve consumer safety through education. By providing patients the latest drug warnings, recalls, studies and litigation news, they can discuss treatment options with their doctor and decide if they need legal advice. It is important to know whether new research is independent or funded by the company selling the drug,“ explains Drugrisks representative Ryan Mayer.
Information on Drugrisks shows health experts still disagree about Pradaxa’s safety and bleeding risks. The FDA recently updated reports to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has cautioned that Pradaxa can increase the risk of bleeding complications compared to warfarin.**
The resource center also recently added a report from the Institute for Safe Medication Practices which ranks blood thinners like Pradaxa among the most dangerous drugs. The institute reviewed nearly 18,000 adverse events reported to the FDA, and discovered patients with bleeding from Pradaxa were nearly 5 times as likely to die than those with warfarin bleeding.***
Due to the number of patients filing a Pradaxa lawsuit over bleeding side effects, the cases have been consolidated to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, Drugrisks has learned of a new study funded by Boehringer Ingelheim, the maker of Pradaxa. While this study at McMaster University in Ontario, Canada only tracked 2,800 patients, it concluded that Pradaxa is safer than warfarin and has less-severe bleeding results.****
Patients are urged to review all available research and speak with their doctor about the reliability of any drug safety studies.
Anyone affected by Pradaxa internal bleeding is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, Drugrisks only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.Drugrisks.com.
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf